Solventum Stock News

Solventum Corporation (NYSE:SOLV ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan C. Hanson - CEO & Director Wayde D.

Solventum (SOLV) Fiscal Q2 EPS Jumps 8%

Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses.

Reported sales increased 3.9%; organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST. PAUL, Minn.

Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimat...

ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close.

Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's  three-phased Transformation Plan ST. PAUL, Minn.

ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46th Annual Global Health Care Conference on Tuesday, June 10, 2025, beginning at approximately 4:00 p.m.